117 related articles for article (PubMed ID: 10520004)
1. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.
Turesson I; Abildgaard N; Ahlgren T; Dahl I; Holmberg E; Hjorth M; Nielsen JL; Odén A; Seidel C; Waage A; Westin J; Wislöff F
Br J Haematol; 1999 Sep; 106(4):1005-12. PubMed ID: 10520004
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.
Pulkki K; Pelliniemi TT; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Br J Haematol; 1996 Feb; 92(2):370-4. PubMed ID: 8603002
[TBL] [Abstract][Full Text] [Related]
3. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
4. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
[TBL] [Abstract][Full Text] [Related]
5. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma.
Kyrtsonis MC; Dedoussis G; Zervas C; Perifanis V; Baxevanis C; Stamatelou M; Maniatis A
Br J Haematol; 1996 May; 93(2):398-400. PubMed ID: 8639436
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A
Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
8. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
Wierzbowska A; Urbańska-Ryś H; Robak T
Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
[TBL] [Abstract][Full Text] [Related]
9. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein.
Kyriakou D; Papadaki H; Eliopoulos AG; Foudoulakis A; Alexandrakis M; Eliopoulos GD
Int J Hematol; 1997 Oct; 66(3):367-71. PubMed ID: 9401283
[TBL] [Abstract][Full Text] [Related]
12. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
[TBL] [Abstract][Full Text] [Related]
13. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG).
Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias.
Ohtani K; Ninomiya H; Hasegawa Y; Kobayashi T; Kojima H; Nagasawa T; Abe T
Br J Haematol; 1995 Sep; 91(1):116-20. PubMed ID: 7577617
[TBL] [Abstract][Full Text] [Related]
15. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
Pelliniemi TT; Irjala K; Mattila K; Pulkki K; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Blood; 1995 Feb; 85(3):765-71. PubMed ID: 7530507
[TBL] [Abstract][Full Text] [Related]
16. Prognosis in myeloma.
Greipp PR
Mayo Clin Proc; 1994 Sep; 69(9):895-902. PubMed ID: 8065197
[TBL] [Abstract][Full Text] [Related]
17. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study.
Pulsatelli L; Boiardi L; Assirelli E; Pazzola G; Muratore F; Addimanda O; Dolzani P; Versari A; Casali M; Magnani L; Pignotti E; Pipitone N; Croci S; Meliconi R; Salvarani C
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):102-110. PubMed ID: 28466804
[TBL] [Abstract][Full Text] [Related]
19. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.
Stephens OW; Zhang Q; Qu P; Zhou Y; Chavan S; Tian E; Williams DR; Epstein J; Barlogie B; Shaughnessy JD
Blood; 2012 Jan; 119(2):503-12. PubMed ID: 22072558
[TBL] [Abstract][Full Text] [Related]
20. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
Gaillard JP; Bataille R; Brailly H; Zuber C; Yasukawa K; Attal M; Maruo N; Taga T; Kishimoto T; Klein B
Eur J Immunol; 1993 Apr; 23(4):820-4. PubMed ID: 8458373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
